Description: Synvisc Injections (Hylan GF 20) is a sterile, pyrogen-free, viscoelastic fluid containing Gilan. Gilan is a derivative of hyaluronan (sodium salt of hyaluronic acid) and consists of repeating disaccharide units N-atsetilglikozamina glyukuronata and sodium. The molecular weight of Hylan A nearly 6 million Hylan B is a hydrated gel. Synvisc Injections contains Hylan A and B Gillan (8.0 mg ± 2,0 mg / 1 mL), diluted in physiological solution of sodium chloride (pH 7,2 ± 0,3).
Feature: Synvisc is a biological analogue of hyaluronan. Hyaluronan – a component of synovial fluid, contributing to its viscoelastic properties. Mechanical (viscoelastic) properties of Synvisc, however, higher than those of synovial fluid and hyaluronan solutions at comparable concentrations. Synvisc Injections has elasticity (the coefficient of G ¢) 111 ± 13 Pascal (Pa) and viscosity (the coefficient of G ¢ ¢) 25 ± 2 Pa, measured at a frequency of 2.5 Hz. Elasticity and viscosity of synovial fluid of persons aged 18-27 years, measured by the same method and at the same frequency are, respectively: G ¢ = 117 ± 13 Pa and G ¢ ¢ = 45 ± 8 Pa. Hylan GF 20 excreted the same ways that Hylan, and its decay products are not toxic.
Indications: Synvisc is intended to temporarily replace or supplement the synovial fluid. Synvisc is indicated in patients suffering from osteoarthritis at any stage of the flow. Synvisc is most effective in the treatment of patients with active lifestyle and regularly load on the affected joint. Synvis Injections c is intended only for intra-articular injection for the treatment of pain caused by osteoarthritis of the knee.
Therapeutic effect: Synvisc Injections associated with \ “the completion of the viscosity, \”, whereby the improved rheological and physiological status of tissues of the affected joint. Completion of the viscosity when administered Synvisc reduces pain and discomfort with subsequent improvement of the function of the affected joint. In vitro studies have shown that Synvisc protects articular cartilage from mechanical and chemical damage. Contra Introduction Synvisc is contraindicated in the presence of venous or lymphatic stasis on the side of the affected joint. Should not be administered Synvisc Injections into infected or severely inflamed joints, as well as the presence of signs of skin infection in the immediate vicinity of the injection site.
Warning: Not for intravascular injection. Synvisc Injections should not be given extra-articular, including, in the synovial tissue or joint capsule. In this case, there may be local adverse reactions.
Caution: Do not enter Synvisc in the presence of significant intra-articular effusion. As well as after any other invasive procedures on the joints, after injection of Synvisc recommend the patient to adhere to gentle treatment and avoid unnecessary burdens on the joint for several days. Synvisc Injections are not used for the treatment of pregnant women and children under 18 years old. Synvisc contains small amounts of chicken protein, and therefore the treatment of patients with hypersensitivity appropriate caution.
Side Effects: After injection of Synvisc can take place a short-term pain, swelling at the injection site and / or the emergence of intra-articular exudation. In some cases, exudation may be significant and cause more prolonged pain. In these cases it is necessary to produce a puncture of the joint and removing fluid from it followed by microscopy to exclude infection and microcrystalline arthropathy (gout). Usually, such reactions are completely disappear within a few days and do not affect the effectiveness of treatment. In clinical trials the drug was not been a single case of infection after injection Synvisc Injections, and for clinical use reported only a few such cases.
Application: Before injection, intra-articular Synvisc remove exudate, if any. Do not use Synvisc if the package opened or damaged. Introduction Synvisc carried out at room temperature. Introduction Synvisc is aseptic procedure, so exercise proper caution when removing the protective cap from the syringe. Use the appropriate needle size (18 to 22). To prevent leakage of the drug during administration hold the cannula tip in close contact with the syringe. Do not expose the Synvisc re-sterilization. Enter Synvisc Injections strictly in joint space. The contents of the syringe is intended for single use.
Dosage: The recommended course of treatment with Synvisc includes three injections into the cavity of the knee joint with an interval of 1 week. For maximum effect, must complete all three shots. The maximum recommended dose – six injections over six months with an interval between the courses of at least 4 weeks. The duration of effect in patients responding to treatment, usually at least twenty-six weeks, but often these terms are more persistent. Treatment Synvisc Injections only affects the affected joint, which introduces the drug, systemic effect Synvisc did not cause.
Shelf life: Store at 2 ° C to 30 ° C. Do not freeze.
